Joe Rogan Experience #2553 - Andrew Hubermsan · Aired Sep 14, 2026
Claim summary · not a verbatim quotation
There have been at least two deaths associated with ibogaine clinics that appear to correlate with prior fentanyl use.
The finding
What the evidence shows
The mechanism described is right. The main danger with ibogaine is cardiac, because it stretches out the heart's electrical cycle and can trigger a fatal rhythm, and fatal cases have clustered around existing heart disease and the use of other depressants including opioids. The number is the problem. A forensic review documented 19 deaths closely linked in time to ibogaine, and later tallies run into the dozens, most of them in treatment or detox settings. Two is a floor rather than a picture of what has been reported, and no published work singles out fentanyl specifically as the link.
Read the supporting source · pmc.ncbi.nlm.nih.gov ↗Quick answer & review status
Quick answer
Is it true that there have been at least two deaths associated with ibogaine clinics that appear to correlate with prior fentanyl use?
Partly. The claim stretches what the evidence shows. The mechanism described is right. The main danger with ibogaine is cardiac, because it stretches out the heart's electrical cycle and can trigger a fatal rhythm, and fatal cases have clustered around existing heart disease and the use of other depressants including opioids. Andrew Hubermsan said it (matched by voice) on Joe Rogan Experience #2553 - Andrew Hubermsan, aired Sep 14, 2026, at 23:04. The supporting source is pmc.ncbi.nlm.nih.gov, linked below.
The context belongs here.
No separately verified on-air correction is recorded for this check. That is not a claim that nobody corrected it.
- Attribution
- Not independently confirmed in this record
- Editorial context review
- Not recorded; generated finding
- Coverage
- One selected claim from the episode
Revisions to this check
No dated revision is recorded here. Older checks may predate this log.
Challenge this finding or add context →Keep the evidence coming.
Follow new checks in your RSS reader, or catch up with the weekly briefing on the site.
Email signup is currently unavailable.
Prefer to catch up here? Read the weekly briefing.